Form 4: Immunome Director Jean Jacques Bienaime Granted Stock Options

Immunome Inc. Director Jean Jacques Bienaime was granted 18,864 stock options with an exercise price of $9.57, vesting quarterly over one year.

Summary

• Immunome Inc. (IMNM) Director Jean Jacques Bienaime was granted 18,864 Director Stock Options.
• The options have an exercise price of $9.57 per share.
• The grant date for these options was June 10, 2025.
• The options will vest in four equal quarterly installments, commencing from June 10, 2025, over a one-year period, subject to continuous service.
• The expiration date for these options is June 9, 2035.
• Following this transaction, Mr. Bienaime beneficially owns 18,864 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of alignment between the board and shareholder interests, and it represents a routine compensation practice without any negative implications.

Positives

• The grant of 18,864 stock options to Director Jean Jacques Bienaime aligns his interests with those of shareholders, incentivizing long-term performance.
• The options have a 10-year expiration period (until June 9, 2035), providing a long window for potential value realization.

Negatives

• N/A (This Form 4 filing reports a routine insider equity grant and does not contain negative company-specific news.)

Risks

• N/A (This document is a Form 4, which reports insider transactions and does not typically detail company-specific risks.)

Future Outlook

The vesting schedule, which extends over one year from June 10, 2025, indicates an expectation of continued service from Director Jean Jacques Bienaime, aligning his incentives with the company's long-term performance.

Management Comments

• N/A (Form 4 is a regulatory filing reporting a transaction, not a statement with management commentary.)

Industry Context

This Form 4 filing reports a routine equity grant to a director, a common practice in the biotechnology and pharmaceutical industries to align executive and board member incentives with shareholder value creation. Such grants are standard compensation components for board members in publicly traded companies.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice in the biotechnology sector, comparable to how other public companies incentivize their board members.
• The exercise price of $9.57 is likely based on the market price of Immunome Inc. (IMNM) common stock on the grant date, which is a typical method for setting option exercise prices.
• The 10-year term for the options is a common duration for employee and director stock options across various industries, including biotech.
• The quarterly vesting over one year is a common short-to-medium term vesting schedule for director equity grants, designed to retain and incentivize continuous service.

Management Changes

Corporate Governance

Legal Proceedings

• N/A (This document is a Form 4 and does not contain information on legal proceedings.)

Related Party Transactions

• The grant of stock options to Jean Jacques Bienaime, a Director of Immunome Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders by incentivizing long-term stock price appreciation.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation philosophy that can attract and retain talent.

Next Steps

• The stock options will vest in four quarterly installments, commencing from June 10, 2025, subject to continuous service with the Company.

Key Dates

Recommendation

Keywords

Immunome, IMNM, stock options, insider transaction, Form 4, director, equity grant, beneficial ownership